Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter: 10 X users

Readers on

mendeley: 4 Mendeley

Summary X

So far, Altmetric has seen 11 X posts from 10 X users, with an upper bound of 45,300 followers.

RT @FrontOncology: New research: Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immu…

19 Oct 2023

Reply Repost Favourite

New research: Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C: Approximately 20% of lung adenocarcinomas harbor activating… https://t.co/xB

19 Oct 2023

Reply Repost Favourite

RT @MariaSaigi: 🔬Our study about Lung Cancer patients with KRAS mutations: KRAS G12C vs. non-G12C, treated with immunotherapy, is out at @F…

18 Oct 2023

Reply Repost Favourite

RT @MariaSaigi: 🔬Our study about Lung Cancer patients with KRAS mutations: KRAS G12C vs. non-G12C, treated with immunotherapy, is out at @F…

18 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 7 additional X posts.